Stay updated with breaking news from Clinical Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call Transcript May 2, 2024 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.41513 EPS, expectations were $-0.31. Zymeworks Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. […]
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS ...
/PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today...
A significant milestone has been reached by Olden Labs as it steps into the limelight revealing its refreshing approach to animal research.